Gilead Sciences Inc. reported $873 million in third-quarter sales of its coronavirus therapy Veklury, above analysts’ expectations, as the company transitions to commercial sales for the medicine. Gilead shares rose 1.8% in late trading; the stock has fallen 9.6% this year through Wednesday’s close.